These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 27030364

  • 1. A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin.
    Maeda A, Ura T, Asano C, Haegawa I, Nomura M, Komori A, Narita Y, Taniguchi H, Kadowaki S, Muro K, Horio Y, Yoshida T, Oze I, Kajita M, Mizutani A.
    Asia Pac J Clin Oncol; 2016 Sep; 12(3):254-8. PubMed ID: 27030364
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
    Abe M, Hirashima Y, Kasamatsu Y, Kado N, Komeda S, Kuji S, Tanaka A, Takahashi N, Takekuma M, Hihara H, Ichikawa Y, Itonaga Y, Hirakawa T, Nasu K, Miyagi K, Murakami J, Ito K.
    Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
    [Abstract] [Full Text] [Related]

  • 3. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Navari RM, Nagy CK, Gray SE.
    Support Care Cancer; 2013 Jun; 21(6):1655-63. PubMed ID: 23314603
    [Abstract] [Full Text] [Related]

  • 4. A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.
    Nakashima K, Murakami H, Yokoyama K, Omori S, Wakuda K, Ono A, Kenmotsu H, Naito T, Nishiyama F, Kikugawa M, Kaneko M, Iwamoto Y, Koizumi S, Mori K, Isobe T, Takahashi T.
    Jpn J Clin Oncol; 2017 Sep 01; 47(9):840-843. PubMed ID: 28633504
    [Abstract] [Full Text] [Related]

  • 5. The Efficacy of Palonosetron Plus Dexamethasone in Preventing Chemoradiotherapy-induced Nausea and Emesis in Patients Receiving Daily Low-dose Cisplatin-based Concurrent Chemoradiotherapy for Uterine Cervical Cancer: A Phase II Study.
    Mitsuhashi A, Usui H, Nishikimi K, Yamamoto N, Hanawa S, Tate S, Watanabe-Nemoto M, Uno T, Shozu M.
    Am J Clin Oncol; 2017 Apr 01; 40(2):118-121. PubMed ID: 25144265
    [Abstract] [Full Text] [Related]

  • 6. The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
    Miura S, Watanabe S, Sato K, Makino M, Kobayashi O, Miyao H, Iwashima A, Okajima M, Tanaka J, Tanaka H, Kagamu H, Yokoyama A, Narita I, Yoshizawa H.
    Support Care Cancer; 2013 Sep 01; 21(9):2575-81. PubMed ID: 23644992
    [Abstract] [Full Text] [Related]

  • 7. A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy.
    Maemondo M, Masuda N, Sekine I, Kubota K, Segawa Y, Shibuya M, Imamura F, Katakami N, Hida T, Takeo S, PALO Japanese Cooperative Study Group.
    Ann Oncol; 2009 Nov 01; 20(11):1860-6. PubMed ID: 19561037
    [Abstract] [Full Text] [Related]

  • 8. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY.
    Intern Med J; 2013 Jan 01; 43(1):73-6. PubMed ID: 22141732
    [Abstract] [Full Text] [Related]

  • 9. Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
    Roila F, Ruggeri B, Ballatori E, Fatigoni S, Caserta C, Licitra L, Mirabile A, Ionta MT, Massidda B, Cavanna L, Palladino MA, Tocci A, Fava S, Colantonio I, Angelelli L, Ciuffreda L, Fasola G, Zerilli F.
    Ann Oncol; 2015 Jun 01; 26(6):1248-1253. PubMed ID: 25743855
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC).
    Karthaus M, Tibor C, Lorusso V, Singh-Arora R, Filippov A, Rizzi G, Borroni ME, Rossi G, Grunberg SM.
    Support Care Cancer; 2015 Oct 01; 23(10):2917-23. PubMed ID: 25724407
    [Abstract] [Full Text] [Related]

  • 12. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.
    Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, Nakao M, Sakai H, Nakayama T, Minato K, Arai T, Suzuki K, Shimada Y, Nagashima K, Terakado H, Yamamoto N.
    Int J Clin Oncol; 2018 Apr 01; 23(2):382-388. PubMed ID: 29039073
    [Abstract] [Full Text] [Related]

  • 13. Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy.
    Yang CK, Wu CE, Liaw CC.
    Biomed J; 2016 Feb 01; 39(1):60-6. PubMed ID: 27105599
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.
    Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen MT, Bubalo J.
    Support Care Cancer; 2007 Nov 01; 15(11):1293-1300. PubMed ID: 17436025
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy.
    Hamada S, Hinotsu S, Kawai K, Yamada S, Narita S, Kamba T, Nishiyama H, Arai Y, Habuchi T, Ogawa O, Kawakami K.
    Support Care Cancer; 2014 Aug 01; 22(8):2161-6. PubMed ID: 24652048
    [Abstract] [Full Text] [Related]

  • 19. Single-dose palonosetron and dexamethasone in preventing nausea and vomiting induced by moderately emetogenic chemotherapy in breast and colorectal cancer patients.
    Brugnatelli S, Gattoni E, Grasso D, Rossetti F, Perrone T, Danova M.
    Tumori; 2011 Aug 01; 97(3):362-6. PubMed ID: 21789017
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.
    Kusagaya H, Inui N, Karayama M, Fujisawa T, Enomoto N, Kuroishi S, Nakamura Y, Matsuda H, Yokomura K, Koshimizu N, Toyoshima M, Imokawa S, Yamada T, Shirai T, Hayakawa H, Suda T.
    Lung Cancer; 2015 Dec 01; 90(3):410-6. PubMed ID: 26791800
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.